News
Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...
The European Medicines Agency has recommended the approval of lenacapavir, a new bi-annual injectable drug aimed at ...
12hon MSN
EU regulator approves injectable HIV drug lenacapavir that experts say could help stop transmission
Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...
LONDON -- The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, ...
In 2024, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...
HIV prevention is entering a new phase with the rise of innovative medications like the twice-yearly injectable lenacapavir.
The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...
17h
InvestorsHub on MSNPositive CHMP Opinion for Gilead’s Lenacapavir in HIV Prevention
Gilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for ...
Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...
Gilead on Friday said the recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use covers lenacapavir for use as pre-exposure prophylaxis, or PrEP, to reduce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results